Merck highlights subcutaneous demand even as Keytruda sales soar

Merck said Keytruda sales jumped 21% to $6.6 billion in the fourth quarter of the year, driven by new approvals in earlier-stage indications for breast cancer and renal cell carcinoma, and more demand in metastatic cancers.

The company’s crown jewel made up nearly half of its revenue in the final…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks